Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Tuning Entry, Shaping Outcome: Receptor-scale control of brain myeloid fate and pathology in Alzheimer’s

Project description

Programming brain immune cells to repair Alzheimer’s disease

The brain harbours specialised immune cells that maintain neural health and respond to disease. In Alzheimer's disease, this immune balance is disrupted, with inflammatory cells infiltrating the brain and accelerating damage. There are two resident immune populations, microglia and border-associated macrophages, that play complementary yet distinct protective roles. However, it remains unknown what determines whether incoming immune precursors develop into one type or the other. With the support of the Marie Skłodowska-Curie Actions programme, the myeloFateTune project aims to identify the key molecular players of human brain immune cell development. The goal is to programme human monocytes to adopt beneficial brain immune identities before reinfusion, thereby establishing a realistic cell-based therapeutic strategy for Alzheimer’s disease.

Objective

Alzheimer’s disease upends the brain’s immune balance by admitting peripheral myeloid cells that intensify inflammation and damage. Two resident guardians from identical ontogeny, microglia in the parenchyma and border-associated macrophages at the brain’s interfaces, are non-redundant and normally sustain synapses and neurovascular health. Yet we still lack a human map of the receptor cues that decide whether incoming precursors settle as microglia or as border macrophages, and how that allocation shapes disease.

This fellowship will close that gap. I will use a human microglia xenotransplantation model in which PSC-derived primitive myeloid precursors engraft into neonatal mouse brains, then apply a focused pooled CRISPR screen with high-parameter fate readouts to build the first receptor-to-fate atlas inside a living mammalian brain. Top receptor 'levers' will be rebuilt in arrayed lines and tested head to head by mosaic co-engraftment to obtain within-brain effect sizes. Fate will be coupled to function at Alzheimer-relevant endpoints such as plaque compaction, antigen presentation, lipid and oxidative tone, synaptic integrity, and vascular reactivity. Finally, I will translate these levers by programming primary human monocytes ex vivo to bias them toward microglia-like or border-like identities, followed by reinfusion, providing a realistic route for cell-based therapy. Together these steps convert descriptive atlases into manipulable circuitry and establish causal, human-specific checkpoints that steer myeloid allocation in vivo.

By showing that allocation can be tuned and that tuning improves repair-linked programs, this project will deliver a therapeutic concept and a deployable toolkit: validated levers, minimal spectral panels, an identity scoring codebase, and FAIR data and protocols for the community. It will also accelerate my transition to independence at the interface of neuroimmunology, functional genetics, and high-dimensional cytometry.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

VIB VZW
Net EU contribution
€ 216 240,00
Address
SUZANNE TASSIERSTRAAT 1
9052 ZWIJNAARDE - GENT
Belgium
Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Activity type
Research Organisations
Links
Total cost
No data